+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

US Breast Cancer Diagnostics And Therapeutics Market 2019-2025

  • ID: 5116814
  • Report
  • February 2020
  • Region: United States
  • Orion Market Research Private Limited

FEATURED COMPANIES

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • Halozyme, Inc
  • Hologic Inc.
US Breast Cancer Diagnostics And Therapeutics Market Size, Share & Trends Analysis Report by Cancer Type (DCIS, IDC, TNBC), Inflammatory Breast Cancer and Others), By Diagnostics (Mammography, Biopsy, PET/CET, Ultrasound, and Others), By Therapeutics(Laboratory testing and Point of care testing) and Forecast 2019-2025.

US breast cancer diagnostics and therapeutics market are estimated to grow significantly at a CAGR of 9.7% during the forecast period. The factors that enable the growth of the market include the prevalence of breast cancer and the initiative by the government and private organizations. Breast cancer is the most commonly diagnosed cancer type in the US. According to the American Cancer society, it is estimated that about 30% of newly diagnosed cancers in women are breast cancer in 2017. About 266,120 new cases of invasive breast cancer and about 63,960 cases of non-invasive breast cancer estimated in 2018 by the American Cancer Society. About 40,920 women died from breast cancer in 2018. The awareness program by the government and research funding also plays an important role in the growth of the breast cancer market in the US. The organization that is contributing to the breast cancer research funding and awareness program includes American Cancer Organization, National Cancer Institute (NCI), Susan G. Komen and others. American cancer provides 162 research grants for breast cancer and funded about $91 million for research in breast cancer.

US breast cancer diagnosis and therapeutics market are segmented on the basis of cancer type, diagnostics, and therapeutics. In cancer type segment market is further classified into ductal carcinoma in-situ (DCIS), invasive ductal carcinoma (IDC), triple negative breast cancer (TNBC), inflammatory breast cancer and others. In diagnostics technology, the segment market is further classified into mammography, biopsy, position emission tomography/Computed tomography, ultrasound, and others. The therapeutics technology segment market is further segregated into chemotherapy, hormone therapy, targeted therapy, and others.

The companies which are contributing to the growth of the US breast cancer diagnostics and therapeutics market include, AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Co., Eli Lilly and Co., Hologic Inc., Halozyme, Inc, Johnson & Johnson Services Inc., Merck & Co., Inc., Pfizer Inc.and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.

Research Methodology:

The market study of US breast cancer diagnostics and therapeutics market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for biotechnology companies, research institutes, hospitals, and government organizations for the overall market and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

1. US breast cancer diagnostics and therapeutics Market Research and Analysis by Cancer Type
2. US breast cancer diagnostics and therapeutics Market Research and Analysis by Diagnostics
3. US breast cancer diagnostics and therapeutics Market Research and Analysis by Therapeutics

The Report Covers:
  • Comprehensive Research Methodology of the US breast cancer diagnostics and therapeutics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the US breast cancer diagnostics and therapeutics market.
  • Insights about market determinants which are stimulating the US breast cancer diagnostics and therapeutics market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • Hologic Inc.
  • Halozyme, Inc
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Siemens Healthcare GmbH
Note: Product cover images may vary from those shown